These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15868995)

  • 21. Serotonin syndrome associated with nefazodone and paroxetine.
    John L; Perreault MM; Tao T; Blew PG
    Ann Emerg Med; 1997 Feb; 29(2):287-9. PubMed ID: 9018197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rare case of serotonin syndrome with therapeutic doses of paroxetine.
    Paruchuri P; Godkar D; Anandacoomarswamy D; Sheth K; Niranjan S
    Am J Ther; 2006; 13(6):550-2. PubMed ID: 17122538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin syndrome with elevated paroxetine concentrations.
    Velez LI; Shepherd G; Roth BA; Benitez FL
    Ann Pharmacother; 2004 Feb; 38(2):269-72. PubMed ID: 14742765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in serotonin receptor expression in the brainstem may explain the differential ability of a serotonin agonist to block seizure-induced sudden death in DBA/2 vs. DBA/1 mice.
    Faingold CL; Randall M; Mhaskar Y; Uteshev VV
    Brain Res; 2011 Oct; 1418():104-10. PubMed ID: 21920504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
    Murata Y; Kobayashi D; Imuta N; Haraguchi K; Ieiri I; Nishimura R; Koyama S; Mine K
    J Clin Psychopharmacol; 2010 Feb; 30(1):11-7. PubMed ID: 20075642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neonatal paroxetine withdrawal syndrome.
    Stiskal JA; Kulin N; Koren G; Ho T; Ito S
    Arch Dis Child Fetal Neonatal Ed; 2001 Mar; 84(2):F134-5. PubMed ID: 11207233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?
    Dahlöf CG; Mathew N
    Cephalalgia; 1998 Oct; 18(8):539-45. PubMed ID: 9827245
    [No Abstract]   [Full Text] [Related]  

  • 28. [Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].
    Freijzer PL; Brenninkmeijer JH
    Ned Tijdschr Geneeskd; 2002 Mar; 146(12):574-5. PubMed ID: 11938583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional consequences of 5-HT transporter gene disruption on 5-HT(1a) receptor-mediated regulation of dorsal raphe and hippocampal cell activity.
    Mannoury la Cour C; Boni C; Hanoun N; Lesch KP; Hamon M; Lanfumey L
    J Neurosci; 2001 Mar; 21(6):2178-85. PubMed ID: 11245702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin toxicity caused by an interaction between fentanyl and paroxetine.
    Rang ST; Field J; Irving C
    Can J Anaesth; 2008 Aug; 55(8):521-5. PubMed ID: 18676387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic paroxetine desensitises 5-HT1D but not 5-HT1B autoreceptors in rat lateral geniculate nucleus.
    Davidson C; Stamford JA
    Brain Res; 1997 Jun; 760(1-2):238-42. PubMed ID: 9237540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study.
    Meyer JH; Kapur S; Eisfeld B; Brown GM; Houle S; DaSilva J; Wilson AA; Rafi-Tari S; Mayberg HS; Kennedy SH
    Am J Psychiatry; 2001 Jan; 158(1):78-85. PubMed ID: 11136637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction.
    Dubovsky SL; Thomas M
    J Psychosom Res; 1995 May; 39(4):429-44. PubMed ID: 7562673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sumatriptan contraindications and the serotonin syndrome.
    Gardner DM; Lynd LD
    Ann Pharmacother; 1998 Jan; 32(1):33-8. PubMed ID: 9475817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple 5-HT(1) autoreceptor subtypes govern serotonin release in dorsal and median raphé nuclei.
    Hopwood SE; Stamford JA
    Neuropharmacology; 2001 Mar; 40(4):508-19. PubMed ID: 11249960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord.
    Castro ME; Pascual J; Romón T; del Arco C; del Olmo E; Pazos A
    Neuropharmacology; 1997; 36(4-5):535-42. PubMed ID: 9225278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Serotonin syndrome with fatal outcome caused by selective serotonin reuptake inhibitors].
    Apelland T; Gedde-Dahl T; Dietrichson T
    Tidsskr Nor Laegeforen; 1999 Feb; 119(5):647-50. PubMed ID: 10095385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition.
    El Mansari M; Blier P
    J Psychiatry Neurosci; 2005 Jul; 30(4):268-74. PubMed ID: 16049570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
    Bogetto F; Bellino S; Revello RB; Patria L
    CNS Drugs; 2002; 16(4):273-83. PubMed ID: 11945110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paroxetine treatment and the prolactin response to sumatriptan.
    Wing YK; Clifford EM; Sheehan BD; Campling GM; Hockney RA; Cowen PJ
    Psychopharmacology (Berl); 1996 Apr; 124(4):377-9. PubMed ID: 8739554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.